

Recent patents in RNA interference

| Patent # | Subject | Assignee | Inventor(s) | Priority application date | Publication date |
|---------------|--|--|--|---------------------------|------------------|
| WO 2002101070 | A method for identifying a compound that modulates T-lymphocyte activation comprising contacting the compound with an alpha integrin-2 polypeptide; useful for diagnosing and treating, for example, autoimmune diseases, infectious diseases, or cancer through gene therapy. | Rigel Pharmaceuticals (S. San Francisco, CA) | Chu P, Li C, Liao XC, Pardo J | 6/7/2001 | 12/19/2002 |
| WO 200299386 | A detection device comprising an array of addressable thermistors, each closely associated with either a first member of a specific binding pair or to a binding or reaction partner to an analyte; provides a real-time, digital profile of the binding or reaction between the analyte and its binding or reaction partner, and is useful for multiparallel thermal analysis of samples, particularly of nucleic acids. | Proligo (Boulder, CO) | Roach JS, Wolter A | 6/7/2001 | 12/12/2002 |
| WO 200297114 | A short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV), or a component of HIV. | Ribozyme Pharmaceuticals (Boulder, CO) | McSwiggen J | 9/10/2001 | 12/5/2002 |
| WO 200296927 | Novel ribozymes that modulate the expression of genes encoding vascular endothelial growth factor and/or VEGF receptor; useful for inhibiting tumor angiogenesis in cells and for treating cancer. | Chiron (Emeryville, CA); Ribozyme Pharmaceuticals (Boulder, CO) | Escobedo J, Gordon G, McSwiggen J, Pavco P, Sandberg J, Stinchcomb D | 5/3/2002 | 12/5/2002 |
| WO 200295071 | A method for determining whether a product of a gene is involved in preventing a replication error in a cell; comprises providing the cell with a specific inhibitor for the product and determining the level of functional expression of a marker gene in the cell, where the level of expression of the marker gene is dependent on the occurrence of the replication error. The identified genes are useful for developing diagnostic tools, or as targets for drug development. | Royal Netherlands Academy of Arts and Sciences (Amsterdam); Tijsterman M | Plasterk RHA | 5/22/2001 | 11/28/2002 |
| WO 200292015 | Compositions and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1 for modulating lipid levels and/or bone mass; useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis. | Genome Therapeutics (Waltham, MA); Wyeth (Madison, NJ) | Allen K, Anisowicz A, Bhat BM, Damagnez V, Robinson JA, Yaworsky PJ | 3/4/2002 | 11/21/2002 |
| WO 200288665 | A method to evaluate the specificity of drugs intended to interact with the same molecular target, to identify a molecular target whose function may be modulated to produce a desired biological effect, to refine the determination of drug specificity for a protein molecular target, and to determine differences in drug response of different cell systems. | Jarvis TC; Thompson JD; Impact Biosciences (Boulder, CO) | Jarvis TC, Thompson JD | 5/1/2001 | 11/7/2002 |
| WO 200283862 | A method for identifying a gene having a mutation causing nonsense-mediated premature protein termination; useful for identifying genes responsible for genetic disorders. | Johns Hopkins University School of Medicine (Baltimore, MD) | Dietz HC, Mendell J, Noensie E | 4/13/2001 | 10/24/2002 |
| WO 200281641 | A gene (SCC-112) that is a modulator of tumor growth and metastasis in certain cancer types; useful for diagnostic and therapeutic applications in detecting and treating cancers that involve expression of SCC-112, such as breast and kidney cancers. | Georgetown University (Washington, DC) | Ahmad I, Kasid UN, Kumar D | 4/6/2001 | 10/17/2002 |

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, Va 22314. Tel: 1 (800) DERWENT (info@derwent.com).